The galectin-3 inhibitor GB0139, which targets idiopathic pulmonary fibrosis, is also in clinical phase IIb (ClinicTrials.gov Identifier: NCT03832946). The gene discussed is LGALS3; the disease is idiopathic pulmonary fibrosis.